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Abstract. Preoperative chemoradiotherapy (CRT) followed 
by mesorectal excision is the standard treatment for patients 
with locally advanced rectal cancer (LARC). The balance 
between treatment efficacy and toxicity is a major issue in the 
clinical management of these patients. There is a requirement 
for the identification of predictive molecular biomarkers for 
the response of patients to CRT. The present study aimed to 
analyze the association between microRNA (miRNA/miR) 
expression and treatment efficacy in patients with LARC who 
were treated with preoperative CRT. From previous clinical 
trials, 55 patients for the test cohort and 130 patients for the 
validation cohort met the criteria for the present investigation. 
Through reverse transcription‑quantitative polymerase chain 
reaction analysis, the expression of miR-21, -31, -125b, -145 
and -630 in the diagnostic biopsies was analyzed. The primary 
endpoint of tumor regression was evaluated according to 
Mandard's Tumor Regression Grade (TRG) system. In the test 
cohort, a significant association was identified between low 
miRNA-145 expression and TRG1+2 (P=0.0003). Similarly, 
this association was identified in the validation cohort, 
although it did not reach statistical significance. Furthermore, 
a significant association between high miRNA‑21 expression 
and TRG1+2 (P=0.035) was observed in the validation cohort. 
The remaining miRNAs analyzed were not associated with 
TRG. The results of the present study highlight the clinical 
importance of miRNAs in LARC and underline the necessity 
for validation studies in this setting.
Introduction
Preoperative 5‑fluorouracil‑based chemoradiotherapy (CRT) 
followed by mesorectal excision is the standard treatment for 
patients with locally advanced rectal cancer (LARC) (1-3). 
Several previous studies have demonstrated that CRT signifi-
cantly downstages the disease and reduces the risk of local 
tumor recurrence (4-6). The response rate to CRT in this group 
varies, with 9-30% of patients having a pathological complete 
response (pCR) and 46‑60% achieving some degree of tumor 
downstaging (7,8). An improved long‑term outcome has been 
demonstrated for patients with pCR compared with patients 
who are non-responsive to CRT (9-12); however, this treatment 
has several long-term side effects. Therefore, the appropriate 
selection of patients who will respond to CRT is important. 
At present, only certain clinical parameters and radiological 
investigations are available for use in the selection of patients 
for CRT, which is insufficient. There is a requirement for 
biomarkers that are able to predict the effect of preoperative 
CRT.
MicroRNAs (miRNAs/miRs) are short (18‑25 nucleo-
tides) non‑coding RNA molecules that act as negative gene 
regulators at the post‑transcriptional level. miRNAs serve an 
important role in the regulation of biological processes, such 
as cell differentiation, proliferation and apoptosis. Numerous 
miRNAs interfere with the expression of oncogenes and 
tumor suppressor genes with a direct involvement in carcino-
genesis (13,14). Due to their association with cancer, miRNAs 
are being investigated as potential diagnostic and prognostic 
biomarkers, and predictors of treatment response (15,16).
In the present study, 5 miRNAs were chosen for study based 
on the literature and our group's previous methodological 
work. In rectal cancer tissue, reference genes (miR‑193a‑5p, 
miR ‑27a and let‑7g) for the relative quantification of miRNAs 
have previously been identified (17) and the intratumoral 
heterogeneity of the present panel of miRNAs (miR-21, -31, 
-125b, -145 and -630) has been assessed (18).
miRNA-21 is overexpressed in rectal cancer and its 
downregulation following neoadjuvant CRT has been 
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suggested (19-21). Furthermore, overexpression of miRNA‑21 
has been associated with complete tumor regression 
following neoadjuvant CRT (22). Increased expression of 
miRNA-31 has been detected in colorectal cancer (CRC), 
with a positive correlation between its expression and the 
stage of the disease (23,24). In addition, the upregulation 
of miRNA‑125b and miRNA‑145 in rectal cancer tissue 
following neoadjuvant CRT has been reported (19,25). Della 
Vittoria Scarpati et al (26) demonstrated that miRNA-630 
had 100% sensitivity and specificity in selecting patients with 
complete tumor regression following CRT. However, only 
one of the studies described above included a validation of 
their results (22). Consequently, the majority of them serve as 
hypothesis‑generating investigations. The present study aimed 
to analyze the association between miRNA expression and 
the treatment efficacy of preoperative CRT in a test cohort of 
LARC patients, and to subsequently validate the results in an 
independent cohort.
Materials and methods
Patient populations. Reporting of all data in the present 
study is in accordance with the Reporting recommenda-
tions for tumor marker prognostic studies criteria (27). The 
present study consisted of a test and a validation cohort of 
patients with LARC. The patients were enrolled in previously 
conducted clinical trials, and the details of patients, treatment 
and follow‑up interval times are available from the pertaining 
publications (28-30). Briefly, the test cohort began with 
85 patients treated in one of two following trials: i) 50 patients 
(enrollment, November 2002‑June 2004) with resectable 
T3 rectal cancer treated with preoperative CRT (60 Gy/30 
fractions, and concurrent tegafur‑uracil (300 mg/m2) and 
L‑leucovorin (22.5 mg/day) combined with an endorectal 
boost (5 Gy/1 fraction) (28); ii) 35 patients (enrollment, June 
2004‑January 2005) with resectable T3‑4 rectal cancer 
receiving similar treatment combined with the cyclooxy-
genase-2-inhibitor celecoxib (400 mg twice a day) (30). The 
validation cohort (enrollment, March 2005-November 2009) 
was based on a previous randomized phase III trial (29) of 
224 patients with resectable T3-4 rectal cancer receiving 
neoadjuvant CRT (50.4 Gy/28 fractions, and concomitant 
tegafur‑uracil (300 mg/m2) and L‑leucovorin (22.5 mg/day) 
with (arm B) or without (arm A) an endorectal boost (10 Gy/2 
fractions)).
The present study was approved by the Regional 
Committee on Health Research Ethics of Southern Denmark 
and the requirement for written informed consent was waived 
(protocol ID no. S‑20140083). The study was registered 
with The Danish Data Protection Agency and The Danish 
Registry of Human Tissue Utilization was consulted prior 
to any tissue samples being used. The inclusion criteria were 
the availability of formalin‑fixed paraffin‑embedded (FFPE) 
diagnostic biopsies containing adenocarcinoma tissue and 
tumor specimens for the pathological evaluation of tumor 
regression grade (TRG). The exclusion criteria were the pres-
ence of synchronous malignant diseases (with the exception 
of non‑melanoma skin cancer and carcinoma in situ of the 
cervical uterus). A total of 55 and 130 patients from the test 
and validation cohorts, respectively, met the criteria for the 
present investigation. Flowcharts of the study populations are 
presented in Fig. 1 and a summary of their clinicopathological 
characteristics are presented in Table I.
Samples. Diagnostic biopsies from the rectal tumors 
followed routine preservation (FFPE), and were transported 
and stored at room temperature. The median storage duration 
from archiving to analysis was 11.5 years in the test cohort 
and 9 years in the validation cohort. Histological sections 
stained with hematoxylin and eosin (H&E) were examined 
by a pathologist in order to ensure the presence of tumor 
cells in the analyzed sections. From the corresponding tissue 
blocks, 8‑µm‑thick sections were cut for use in subsequent 
reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR) analysis. In the test population, areas of tumor 
cells were identified by a pathologist and encircled as regions 
of interest (ROI) on an image of the H&E‑stained section. 
The ROI were isolated through membrane‑based laser micro-
dissection (LMD) using a Leica LMD6500 Microsystems 
(Leica Microsystems GmbH, Wetzlar, Germany) and 
collected in the caps of 0.5 ml RNase‑free PCR tubes with 
a drop of ethanol (99%). In the validation population, LMD 
was performed as described above. However, in a subset of 
cases in the validation cohort LMD was not required, since 
the whole biopsy consisted of tumor tissue without marked 
inflammation. In these cases (N=26) the tissue was removed 
from the slides using a scalpel and collected into 1.5 ml 
RNase‑free PCR tubes containing a drop of ethanol (99%).
Expression analysis via RT‑qpcr
Normalizer miRNAs. Recently, our group performed a 
study (17) on miRNA expression profiling to identify and 
validate reference genes for the relative quantification of 
miRNAs in rectal cancer tissue. miR‑193a‑5p, miR‑27a and 
let‑7g were identified as the most stably expressed miRNAs 
in rectal cancer tissue, and the mean expression value of these 
three miRNAs were subsequently used for normalization in 
the present study.
RNA extraction. Total RNA was isolated from the FFPE 
tissue using the miRNeasy FFPE kit for the test study and the 
AllPrep DNA/RNA FFPE kit (both Qiagen GmbH, Hilden, 
Germany) for the validation study according to the manufac-
turer's protocol. Total RNA was eluted into 14 µl RNase‑free 
water.
RT‑qPCR. RT and preamplification were performed as previ-
ously described (18). Custom TaqMan® MicroRNA Single 
Assays (Thermo Fisher Scientific, Inc., Waltham, MA, 
USA) for hsa‑let‑7g (cat. no. 002282), hsa‑miR‑193a‑5p (cat. 
no. 002281), hsa-miR-27a (cat. no. 000408), hsa-miR-21 (cat. 
no. 000397), hsa-miR-31 (cat. no. 002279), hsa-miR-125b 
(cat. no. 000449), hsa-miR-145 (cat. no. 002278) and 
hsa‑miR‑630 (cat. no. 001563) were used, according to the 
manufacturer's protocol. The qPCR analyses were carried 
out using a QuantStudio™ 12K Flex Real‑Time PCR system 
(Thermo Fisher Scientific, Inc.) with 1 µl diluted preampli-
fication product, TaqMan MicroRNA Assays and TaqMan® 
Universal Master Mix II NoAmpErase® UNG in a total 
reaction volume of 20 µl. All reactions were performed in 
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triplicate. Data analysis was performed using Quantstudio 
12K Flex software (version 1.2.2; Thermo Fisher Scientific, 
Inc.) and relative quantification was performed using the 
2-ΔΔCq method as described by Eriksen et al (18). The mean 
expression value of miR‑193a‑5p, miR‑27a and let‑7g was 
used as the normalization factor. Water was used as the nega-
tive control. A no‑template control was included in the entire 
process and analyzed together with samples. The analyses 
were performed by staff blinded to the patient outcome.
Endpoints. The primary endpoint of tumor regression was 
determined by assessing the operative specimens according 
to Mandard's Tumor Regression Grade (TRG) system (31,32), 
as follows: TRG1, no residual tumor; TRG2, microscopic 
residual tumor; TRG3, moderate response; TRG4, minor 
response; and TRG5, no response. Overall survival (OS) and 
disease‑free survival (DFS) were the secondary endpoints. 
OS was defined as the time from inclusion in the primary 
study until mortality from any cause. DFS was calculated as 
the time from inclusion in the primary study until the first 
documented tumor progression or mortality from any cause.
Statistical analysis. Wilcoxon rank‑sum test was used for 
comparison of medians between groups. The prognostic 
value of variables was analyzed using the log rank‑test and 
survival curves were produced using the Kaplan‑Meier esti-
mator. Patients with additional malignancies were excluded 
from the DFS analysis (test study, N=9; validation study, 
N=16). Clinical outcome data were last updated in April 
2016. Possible correlations between continuous data were 
analyzed and visualized using the parametric linear regres-
sion analysis. Univariate Cox's regression analysis was used 
to estimate the prognostic value of individual variables 
and those with P<0.1 were included in a multivariate Cox's 
regression analysis for independent prognostic value. All 
tests were two-tailed. All statistical analyses were performed 
using NCSS Statistical Software 2007 (version 07.1.20; 
NSCC, LLC, Kaysville, UT, USA). P<0.05 was considered to 
indicate a statistically significant difference.
Results
Test population. The test cohort analyses consisted of 
55 patients and the treatment compliance was high (28). The 
median follow‑up time was 11.6 years. All patients were 
responsive to preoperative CRT. Patient characteristics and 
treatment responses are presented in Table I. An expression 
of miR‑145 below the median expression level was signifi-
cantly associated with major response (TRG1+2) to treatment 
(P<0.001; Table II). For the other investigated miRNAs no 
significant association between their expression and TRG 
was identified (Table II). For survival analysis, patients 
were grouped according to their median expression of the 
miRNA of interest [above (high) or below (low) the median]. 
No significant difference was identified between the high 
and low expression groups for the investigated miRNAs 
following OS and DFS analyses (data not shown).
Validation population. A total of 130 patients were included 
in the validation population. Patient characteristics and treat-
ment responses are presented in Table I. All patients, with the 
exception of two, received >80% of the planned radiotherapy 
with a curative intent. Eight patients had developed distant 
metastases in the liver and/or lungs at the time of surgery. 
In the validation population, an expression of miR‑21 above 
the median expression level was significantly associated 
Table I. Clinicopathological characteristics and response to chemoradiotherapy of patients in the test and validation study cohorts.
 Test cohort (N=55),  Validation cohort (N=130),
Clinicopathological characteristic no. of patients (%) no. of patients (%)
Gender  
  Female 19 (34.5) 50 (38)
  Male 36 (65.5) 80 (62)
T-stage  
  T3 48 (87) 110 (85)
  T4 7 (13) 20 (15)
N-stage  
  N0 16 (29) 14 (11)
  N+ 39 (71) 116 (89)
TRG  
  TRG1 13 (23.5) 26 (20)
  TRG2 13 (23.5) 17 (13)
  TRG3 28 (51) 75 (58)
  TRG4 1 (2) 12 (9)
In the test cohort the median age was 62 (range, 40‑78), in the validation cohort the median age was 64 (range, 35‑79). No patients had TRG5. 
TRG, tumor regression grade according to Mandard et al (31); T, tumor; N, node, according to the tumor‑node‑metastasis (TNM) classification 
of malignant tumours (UICC, international union against cancer).
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(P=0.035) with major response (TRG1+2) to treatment 
(Table III). The association between miR‑145 expression and 
TRG was similar to the one demonstrated in the test cohort, 
although it did not reach statistical significance (P=0.085). 
For miR-125b, -31 and -630, no significant association 
between expression and TRG was detected (Table III).
Grouping patients in the validation cohort according to 
their median expression of the miRNA of interest revealed 
that patients with miR-125b and miR-145 expression below the 
median had a significantly better DFS compared with those 
with expression above the median (Table IV). Survival curves 
for miR‑145 are illustrated in Fig. 2. No significant difference 
in DFS was detected for miR‑21, ‑31 and ‑630 (Table IV). No 
significant difference was demonstrated between the high and 
low expression of any of the investigated miRNAs and OS 
(Table IV).
For a parameter to be included in the multivariate Cox's 
regression analysis, a cut‑off significance level of P<0.1 in the 
univariate analysis was pre‑specified. In the linear regression 
analysis, a significant positive correlation was demonstrated 
between miR-125b and miR-145 expression (r=0.73; P<0.0001; 
Fig. 3), and therefore they were included in a separate multi-
variate analysis (Table V). Resection status (P=0.002, Table V) 
and miR‑125b expression (P=0.026, Table V) remained signif-
icant in predicting DFS, and a borderline significance was 
demonstrated for miR‑145 expression (P=0.053). Multivariate 
analysis was not performed for OS, as none of the investi-
gated miRNAs were significantly associated with OS in the 
univariate analysis.
Discussion
The balance between treatment efficacy and toxicity is a major 
issue in the clinical management of patients with LARC. 
Identifying molecular biomarkers capable of predicting the 
response of patients to preoperative CRT is therefore important. 
The ʻwatchful waitingʼ strategy is emerging as an alternative 
the typical preoperative CRT followed by surgery; thus far, a 
number of studies have revealed encouraging outcomes for this 
strategy (33-37). If tumor response to neoadjuvant CRT could 
be predicted it would facilitate in providing more individual-
ized treatment planning, whereby patients with pCR could 
avoid the standard resection procedure, which is frequently 
followed by a high risk of morbidity.
It has previously been demonstrated by Ryan et al (38) that 
patients with TRG1 and TRG2 tumors can be regarded as having 
pCR to preoperative CRT. In addition, Lindebjerg et al (39) 
demonstrated that 28% of tumors originally classified as 
TRG1 were reclassified as TRG2 tumors following step 
sectioning (39). Based on these results, patients with TRG1 and 
TRG2 were pooled as complete responders in the present study 
and compared with patients with a poorer response (TRG3+4).
In the present study, the expression of selected miRNAs 
in diagnostic biopsies from patients with locally advanced 
T3‑4 rectal cancer was analyzed. The results demonstrated a 
significant association between miR‑145 expression and the 
overall response of patients with rectal cancer to preoperative 
CRT. Furthermore, the results suggest a possible association 
between miR-21 and TRG, and between miR-125b and DFS.
Table III. Association between TRG and miR expression in the validation cohort (N=130). 
 miR expression, median (95% CI)
 -------------------------------------------------------------------------------------------------------------------------------------
miR TRG1+2 TRG3+4 P‑valuea
125b 1.338 (1.009-1.729) 1.566 (1.252-1.922) 0.337
145 18.735 (13.923-22.943) 22.015 (18.164-27.612) 0.085
21 26.861 (22.906-29.768) 21.107 (19.615-22.829) 0.035
3 0.109 (0.072-0.391) 0.135 (0.090-0.210) 0.761
630 0.001 (0.001-0.002) 0.001 (0.001-0.001) 0.333 
aTRG1+2 vs. TRG3+4. TRG, tumor regression grade according to Mandard et al (31); CI, confidence interval; miR, microRNA.
Table II. Association between TRG and miR expression in the test cohort (N=55). 
 miR expression, median (95% CI)
 -------------------------------------------------------------------------------------------------------------------------------------
miR TRG1+2 TRG3+4 P‑value
125b 1.030 (0.558-1.447) 1.708 (0.951-2.026) 0.174
145 9.854 (5.501-13.846) 17.370 (13.515-25.070)  <0.001
21 14.206 (11.529-18.195) 17.463 (16.057-19.450) 0.062
3 0.128 (0.051-0.235) 0.136 (0.066-0.262) 0.463
630 0.004 (0.003-0.005) 0.003 (0.002-0.004) 0.104
TRG, tumor regression grade according to Mandard et al (31); CI, confidence interval; miR, microRNA.
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Figure 2. Kaplan‑Meier survival curves for (A) DFS and (B) OS based on miR‑145 expression. The red curves represent patients with miR expression below the 
median and the blue curves patients with miR expression above the median. miR, microRNA; DFS, disease‑free survival; OS, overall survival.
Figure 1. CONSORT flow diagram of the (A) test and (B) validation populations. miRNA, microRNA.
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In the test cohort, a significant association between low 
miR‑145 expression and major treatment response (TRG1+2) 
was detected. Similarly, this association was identified in the 
validation cohort; however, it did not reach statistical signifi-
cance (P=0.085). Drebber et al (19) reported a significant 
correlation between a major response to neoadjuvant CRT 
and a high level of miR‑145 expression. However, the results 
of this study are difficult to compare with those of the present 
study, since they used a different tumor regression grading 
system (40) and performed macrodissection, whereas the 
majority of the samples in the current study underwent laser 
microdissection.
The significant association between a high expression 
of miR‑21 and TRG1+2 in the validation population is in 
Table IV. Univariate Cox's regression analysis of the association between clinicopathological characteristics and DFS and OS in 
the validation cohort (N=130). 
 DFS OS
 -------------------------------------------------------------------------- -------------------------------------------------------------------------
Clinicopathological characteristic HR 95% CI P‑value HR 95% CI P‑value
Gender  0.50-1.42 0.517  0.64-1.93 0.711
  Female 1   1  
  Male 0.84   1.11  
Age  0.84-2.41 0.187  1.22-3.74 0.008
  <64 1   1  
  ≥64 1.42   2.14  
T-stage  0.78-2.92 0.220  0.47-2.09 0.973
  T3 1   1  
  T4 1.51   0.98  
N-stage  0.44-2.16 0.954  0.42-2.04 0.837
  N0 1   1  
  N+ 0.98   0.92  
Distance from anal verge (cm)  0.42-2.65 0.913  0.54-3.50 0.497
  ≤5 1   1  
  >5 1.05   1.38  
TRG  0.28-0.94 0.032  0.46-1.44 0.473
  TRG1-2 0.52   0.81  
  TRG3-4 1   1  
Resection status  1.81‑7.19 <0.001  1.78‑7.59 <0.001
  R0 1   1  
  Not R0 3.61   3.68  
miR-125b expression  1.14-3.34 0.015  0.74-2.15 0.404
  Above median 1   1  
  Below median 1.95   1.26  
miR-145 expression  1.04-3.03 0.035  0.81-2.37 0.237
  Above median 1   1  
  Below median 1.78   1.38  
miR-21 expression  0.48-1.36 0.418  0.43-1.25 0.255
  Above median 1   1  
  Below median 0.81   0.73  
miR-31 expression  0.75-2.12 0.389  0.74-2.15 0.402
  Above median 1   1  
  Below median 1.26   1.26  
miR-630 expression  0.68-1.96 0.602  0.79-2.32 0.269
  Above median 1   1  
  Below median 1.15   1.35  
DFS, disease‑free survival; OS, overall survival; HR, hazard ratio; TRG, tumor regression grade according to Mandard et al (31); CI, confi-
dence interval; miR, microRNA; T, tumor; N, node.
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accordance with a previous study by Lopes‑Ramos et al (22), 
which revealed that the overexpression of miR-21-5p is predic-
tive of complete tumor regression following neoadjuvant CRT 
in patients with rectal cancer with a sensitivity and specificity 
of 78 and 86%, respectively. Furthermore, Bandres et al (41) 
revealed that an upregulation of miR‑21 was associated with 
TRG1 or TRG2 tumors. The results of the test study popula-
tion in the present study did not identify the same association 
between miR‑21 expression and treatment response. Results 
from the test cohort suggested an association between a low 
expression of miR‑21 and a major treatment response, but this 
did not reach statistical significance. However, in the validation 
population there was a significant association between a high 
miR‑21 expression and a major response to preoperative CRT, in 
agreement with Lopes-Ramos et al (22) and Bandres et al (41).
miR‑125b and miR‑31 were included in the present study 
based on previous literature on miRNAs associated with rectal 
cancer (23-25). In the current study, no association between 
their expression and response to preoperative CRT was 
detected. However, the significant association between a low 
expression of miR-125b and increased DFS in the validation 
cohort requires further investigation.
The results from a study by Della Vittoria Scarpati et al (26), 
which demonstrated that miR-630 had 100% sensitivity and 
specificity in selecting patients having pCR after undergoing 
CRT (N=38), were not confirmed in the current study. The 
expression of miR-630 was analyzed in diagnostic biopsies 
from a total of 185 patients in the present study. In general, 
miR‑630 was sparsely expressed, and it was undetected in 24 
samples. Previously, high intratumoral heterogeneity has been 
reported regarding miR-630 expression in rectal cancer (18).
In conclusion, the partially diverging results between the 
test and the validation cohorts in the present study underline 
the importance of the validation of biomarker studies. This 
issue has not been adequately addressed in the previous 
literature. The majority of studies include <50 patients with 
no validation. The risk of positive results being considered 
false positives in investigations with small cohorts is high. 
This approach has hampered or delayed the clinical applica-
tion of diagnostic and prognostic biomarkers. The results of 
the present study underline the necessity for large prospective 
trials of miRNA biomarkers in the future.
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